文献速递肾移植

Banff 2022 抗体介导排斥反应分类中的活检转录组学

Biopsy-based Transcriptomics in Banff 2022 Antibody Mediated Rejection Categories.
PubMed 文献 · Kidney Int Rep · 2026-05-05

该研究分析562例肾移植活检,用组织学和分子显微镜诊断系统(MMDx)评估Banff 2022 probable AMR及DSA-/C4d-微血管炎(MVI)等分类。结果显示活检转录组学主要反映MVI而非DSA,在probable AMR和MVI阳性活检中尤其有信息价值,且分子模型预测3年移植物存活与组织学模型性能相似。

要点

  • 活检转录组学在probable AMR和MVI阳性活检中提供额外信息。
  • 分子AMR在probable AMR中检出率为24%,在MVI DSA-/C4d-中为43%。
  • 分子与组织学模型预测3年移植物存活性能相似(一致性0.84 vs 0.82)。

核心结论

  • 活检转录组学主要反映微血管炎症而非供者特异性抗体,在probable AMR和MVI阳性活检中尤其有信息价值。

研究设计与样本

  • 研究分析了562例来自布拉格和苏黎世的肾移植活检,采用组织学和分子显微镜诊断系统(MMDx)进行分类。
  • 活检被分为四组:无移植肾小球病(cg)的活动性AMR谱病变、合并cg的活动-慢性病变、无活动性病变的慢性AMR、以及无排斥对照。

主要发现

  • 分子AMR在probable AMR中检出率为24%,在probable AMR伴cg中为23%,在MVI DSA-/C4d-中为43%,在活动性AMR中为51%,在MVI DSA-/C4d-伴cg中为56%,在慢性活动性AMR中为63%,在慢性AMR中仅6%。
  • AMRprob评分在probable AMR中高于对照,在慢性AMR与对照间相似。
  • AMRprob评分在活动性AMR、慢性活动性AMR和MVI DSA-/C4d-组间相当,且这些组的TCMR prob评分均高于probable AMR和对照。
  • 在苏黎世队列训练的LASSO-Cox回归预测3年移植物存活,分子模型(cgprob、ctprob、tprob、AKIscore)与组织学模型(Banff cg、ci、ct、t)性能相似,一致性分别为0.84 vs 0.82;在布拉格队列外部验证为0.78 vs 0.75。

关键数值与推荐

  • 分子AMR检出率:probable AMR 24%,probable AMR伴cg 23%,MVI DSA-/C4d- 43%,活动性AMR 51%,MVI DSA-/C4d-伴cg 56%,慢性活动性AMR 63%,慢性AMR 6%。
  • 预测3年移植物存活的模型一致性:苏黎世队列分子模型0.84 vs 组织学模型0.82;布拉格队列0.78 vs 0.75。

临床怎么用

  • 对于probable AMR和MVI阳性活检,可考虑结合活检转录组学以辅助诊断。
  • 活检转录组学结果解读时应注意其主要反映MVI而非DSA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Biopsy-based transcriptomics (BBT) supports antibody-mediated rejection (AMR) diagnostics, but Banff 2022 probable AMR and donor-specific antibodies (DSA)-/C4d-microvascular inflammation (MVI) remain unvalidated by BBT. METHODS: We analyzed 562 kidney allograft biopsies from Prague and Zurich by histology and Molecular Microscope Diagnostic System (MMDx). Biopsies were classified into the following: (i) active AMR-spectrum lesions without transplant glomerulopathy (cg) (active AMR, probable AMR, MVI, DSA-/C4-); (ii) combined active-chronic lesions with cg (chronic-active AMR, probable AMR with cg, MVI, DSA-/C4d- with cg); (iii) chronic AMR, defined by cg without active lesions; and (iv) controls without rejection. RESULTS: Molecular AMR was detected in 24% of probable AMR and 23% of probable AMR with cg biopsies, 43% of MVI, DSA-/C4d-, 51% of active AMR, 56% of MVI, DSA-/C4d- with cg, and 63% of chronic-active AMR, but was rare in chronic AMR (6%). AMR probability classifier (AMRprob) scores were higher in probable AMR than in controls and similar between chronic AMR and controls. AMRprob scores were comparable among active AMR, chronic-active AMR, and MVI, DSA-/C4d- groups, all of which exhibited elevated T cell-mediated rejection (TCMR) prob scores compared with probable AMR and controls.Least absolute shrinkage and selection operator-penalized Cox regression predicting 3-years graft survival trained in the Zurich cohort showed similar performance of molecular (cgprob, ctprob, tprob, acute kidney injury [AKI]score) and histologic model (Banff cg, interstitial inflammation [ci], tubular atrophy [ct], and tubulitis [t]) (concordance 0.84 vs. 0.82), with the external validation in the Prague cohort (0.78 vs. 0.75). CONCLUSION: BBT primarily reflects MVI rather than DSA and is particularly informative in probable AMR and MVI-positive biopsies.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Hruba P, Girmanova E, Harmacek D, et al. Biopsy-based Transcriptomics in Banff 2022 Antibody Mediated Rejection Categories. Kidney Int Rep. 2026. PMID: 42254850. doi:10.1016/j.ekir.2026.106575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。